Stock Market & Financial Investment News

News Breaks December 28, 2012 10:36 EDT MYL, TEVA Mylan launches generic Nordette 28 tablets Mylan (MYL) announced that its partner Famy Care Ltd. has received final approval from the FDA for its Abbreviated New Drug Application for Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg. This product is the generic version of Teva Branded Pharmaceutical Products' (TEVA) Nordette 28 Tablets, which are indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. The product will be distributed in the U.S. by Mylan Pharmaceuticals Inc., and the company is shipping product immediately. News For MYL;TEVA From The Last 14 Days Check below for free stories on MYL;TEVA the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. May 17, 2013 14:48 EDT MYL Actavis may bid for Warner Chilcott to ward off takeover, Reuters says Subscribe for More Information 13:56 EDT MYL Actavis may purchase Warner Chilcott as takeover defense, Reuters reports Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. 07:31 EDT MYL Mylan launches generic Tricor tablets Subscribe for More Information May 15, 2013 19:37 EDT MYL Novartis weighing Actavis bid, WSJ reports Subscribe for More Information 17:36 EDT MYL Paulson gives quarterly update on stakes Subscribe for More Information 11:42 EDT MYL Mylan launches generic Zomig tablets Subscribe for More Information 07:03 EDT MYL Mylan highly unlikely to acquire Actavis, says Barclays Subscribe for More Information May 14, 2013 13:55 EDT MYL Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says Subscribe for More Information 13:22 EDT MYL Actavis turned down $15B takeover bid from Mylan, Bloomberg reports Subscribe for More Information May 13, 2013 09:44 EDT TEVA Several companies reportedly interested in buying Adcock Ingram, Globes says Subscribe for More Information 07:49 EDT TEVA FDA decision on Opana a modest positive for Impax, says Leerink Leerink views the FDA's denial of Endo's (ENDP) Citizen Petition as a modest positive for Impax (IPXL), which it notes is the sole holder of 180 day exclusivity on generic Opana. However, Leerink says upside for Impax will be limited as Actavis (ACT), Sandoz, and Teva (TEVA) have settlements to enter the market starting in June 2013 when Impax's 180-day generic exclusivity expires. May 10, 2013 10:00 EDT MYL, TEVA On The Fly: Analyst Initiation Summary Today's noteworthy initiations include: 3D Systems (DDD) initiated with a Buy at Janney Capital... Actavis (ACT) initiated with an Outperform at BMO Capital... Allergan (AGN) initiated with an Outperform at BMO Capital... Emeritus (ESC) initiated with an Outperform at Wells Fargo... Ensign Group (ENSG) initiated with a Market Perform at Wells Fargo... Forest Labs (FRX) initiated with an Underperform at BMO Capital... J2 Global (JCOM) initiated with an Outperform at Wedbush... Mylan (MYL) initiated with an Underperform at BMO Capital... Splunk (SPLK) initiated with a Market Perform at FBR Capital... Teva (TEVA) initiated with an Outperform at BMO Capital... Workday (WDAY) initiated with an Outperform at Oppenheimer... Nuance (NUAN) initiated with an Outperform at Wedbush... Demandware (DWRE) initiated with an Outperform at Wedbush... Synchronoss (SNCR) initiated with an Outperform at Wedbush... Trius Therapeutics (TSRX) initiated with a Buy at Guggenheim... Proto Labs (PRLB) initiated with a Buy at Janney Capital... Stratasys (SSYS) initiated with a Buy at Janney Capital. May 9, 2013 16:35 EDT TEVA Teva initiated with an Outperform at BMO Capital Subscribe for More Information 16:34 EDT MYL Mylan initiated with an Underperform at BMO Capital Subscribe for More Information May 8, 2013 12:03 EDT TEVA Teva says data demonstrates ovulatory effect of investigational contraceptive Subscribe for More Information 10:26 EDT TEVA Alexza deal with Teva could be worth $12 per share or more, says Roth Capital Subscribe for More Information 09:06 EDT TEVA Alexza Pharmaceuticals to host conference call Subscribe for More Information 08:33 EDT TEVA Teva, Alexza announce Teva's license to market Adasuve in the U.S. Teva Pharmaceuticals USA, a subsidiary of Teva Pharmaceutical (TEVA), and Alexza Pharmaceuticals (ALXA) announced that the companies have entered into an exclusive U.S. license and supply agreement for Adasuve inhalation powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. Teva will be responsible for all U.S. commercial and clinical activities for Adasuve, including U.S. post-approval clinical studies, and has gained rights to conduct additional clinical trials of Adasuve for potential new indications in neurological disorders. Alexza will be responsible for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials. Under the terms of the license and supply agreement, Alexza will receive an upfront cash payment of $40M and is eligible to receive up to $195M in additional milestone payments, based upon successful completion of the ADASUVE post-approval studies in the U.S. and achieving net sales targets. In addition, Teva will make tiered, royalty payments based on net commercial sales of Adasuve. May 7, 2013 11:50 EDT TEVA Teva rival receives patent for once a month Copaxone Subscribe for More Information May 6, 2013 07:18 EDT TEVA American Congress of Obstetrics and Gynecology to hold annual meeting Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.